<p>Rocket Pharmaceuticals（纳斯达克：RCKT - 获取免费报告）于周四发布了季度财报。这家生物技术公司报告本季度每股收益为（$0.42），低于分析师一致预期的（$0.41），差距为（$0.01），据 Zacks 报道。在去年同期，该公司每股收益为（$0.56）。</p>
<p>获取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
<h2>Rocket Pharmaceuticals 股价下跌 1.1%</h2>
<ul>
<li>3 只准备大幅上涨的小型股</li>
</ul>
<p>周五午盘交易中，RCKT 股票下跌 $0.04，报 $3.63。该股票成交量为 3,682,797 股，较其平均成交量 2,125,075 股有所增加。Rocket Pharmaceuticals 的 52 周低点为 $2.19，52 周高点为 $7.39。该股票的 50 日移动平均线为 $4.09，200 日移动平均线为 $3.69。公司的市值为 $3.9611 亿，市盈率为 -1.94，贝塔值为 0.52。公司的流动比率为 6.38，速动比率为 6.38，债务与股本比率为 0.07。</p>
<h2>华尔街分析师观点</h2>
<p>多位分析师最近对 RCKT 股票发表了评论。Cantor Fitzgerald 将 Rocket Pharmaceuticals 的目标价从 $8.00 上调至 $10.00，并在 2 月 27 日的报告中给予该股票 “超配” 评级。高盛集团在 3 月 2 日的报告中将 Rocket Pharmaceuticals 的目标价上调至 $3.00，并给予该股票 “卖出” 评级。美国银行在 3 月 30 日的研究报告中将 Rocket Pharmaceuticals 的目标价从 $8.00 上调至 $9.00，并给予该股票 “买入” 评级。Wall Street Zen 在 3 月 8 日的报告中将 Rocket Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。最后，Lifesci Capital 在 2 月 26 日的研究报告中将 Rocket Pharmaceuticals 的评级上调至 “强烈买入”。一位投资分析师给予该股票 “强烈买入” 评级，八位分析师给予 “买入” 评级，六位分析师给予 “持有” 评级，三位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Rocket Pharmaceuticals 目前的共识评级为 “持有”，平均目标价为 $11.54。</p>
<p><strong>阅读我们关于 Rocket Pharmaceuticals 的最新报告</strong></p>
<h2>Rocket Pharmaceuticals 的内部活动</h2>
<p>在其他新闻中，首席法律顾问 Martin Wilson 于 2 月 13 日出售了 12,253 股公司的股票，交易发生在该日。股票以平均价格 $3.31 出售，总交易额为 $40,557.43。出售后，首席法律顾问持有 683,376 股公司股票，价值约 $2,261,974.56。此次交易使其持股减少了 1.76%。该交易已在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，首席执行官 Gaurav Shah 于 2 月 13 日出售了 12,279 股公司的股票，交易发生在该日。股票以平均价格 $3.31 出售，总交易额为 $40,643.49。出售完成后，首席执行官持有 1,052,045 股公司的股票，价值约 $3,482,268.95。此次交易使其持股减少了 1.15%。该销售的 SEC 文件提供了更多信息。在过去三个月中，内部人士出售了 29,415 股公司股票，价值 $97,398。目前，21.30% 的股票由内部人士持有。</p>
<h2>Rocket Pharmaceuticals 的机构交易</h2>
<p>对冲基金和其他机构投资者最近调整了对该公司的持股。MPM Bioimpact LLC 在第二季度将其在 Rocket Pharmaceuticals 的持股增加了 141.2%。MPM Bioimpact LLC 目前拥有 3,903,081 股该生物技术公司的股票，价值 $9,563,000，此前在该期间内又购买了 2,284,816 股。Qube Research &amp; Technologies Ltd 在第二季度将其在 Rocket Pharmaceuticals 的持股增加了 690.8%。Qube Research &amp; Technologies Ltd 目前拥有 1,548,262 股该生物技术公司的股票，价值 $3,793,000，此前在上个季度又收购了 1,352,469 股。Millennium Management LLC 在第三季度将其在 Rocket Pharmaceuticals 的持股增加了 52.0%。Millennium Management LLC 目前拥有 3,570,391 股该生物技术公司的股票，价值 $11,639,000，此前在该期间内又购买了 1,221,554 股。Opaleye Management Inc. 在第四季度收购了 Rocket Pharmaceuticals 的新头寸，价值约 $3,352,000。最后，摩根大通在第三季度将其在 Rocket Pharmaceuticals 的持股增加了 73.6%。摩根大通目前拥有 2,097,033 股该生物技术公司的股票，价值 $6,836,000，此前在上个季度又购买了 889,231 股。机构投资者和对冲基金持有该公司 98.39% 的股票。</p>
<h2>Rocket Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Rocket Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于开发针对罕见遗传性儿童疾病的基因疗法。该公司采用专有的腺相关病毒（AAV）和慢病毒载体平台，为患有遗传缺陷的患者提供功能性基因拷贝。其项目针对一系列疾病，包括范可尼贫血、白细胞粘附缺陷 I 型和丹农病，旨在提供一次性治疗，解决疾病的根本原因，而不仅仅是管理症状。</p>
<p>该公司的产品管线包括多个处于不同开发阶段的候选产品。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 Rocket Pharmaceuticals</li>
<li>巴菲特花了 60 年忽视科技，账单即将到来</li>
<li>对黄金感到兴奋但不确定其走势？试试这三种方法</li>
<li>美元处于三年低点：三家出口商悄然印钞</li>
<li>水务基础设施：为什么这个乏味的行业可能会变得令人兴奋</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Rocket Pharmaceuticals 吗？</h2>
<p>在考虑 Rocket Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Rocket Pharmaceuticals 并不在名单上。</p>
<p>虽然 Rocket Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Rocket制药

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

IBBQ

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

<p>Rocket Pharmaceuticals（纳斯达克代码：RCKT）报告的季度每股收益为（$0.42），低于分析师预期的（$0.41），差距为$0.01。这一表现较去年同期的（$0.56）有所改善。该股下跌 1.1%，报$3.63，市值为 3.9611 亿美元。分析师的评级不一，目标价格范围从$3.00 到$11.54。内部交易活动包括总法律顾问 Martin Wilson 和首席执行官 Gaurav Shah 的股票出售。机构投资者在最近几个月显著增加了持股</p>

<p>Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.01), Zacks reports. During the same quarter in the prior year, the business earned ($0.56) EPS.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals（纳斯达克：RCKT - 获取免费报告）于周四发布了季度财报。这家生物技术公司报告本季度每股收益为（$0.42），低于分析师一致预期的（$0.41），差距为（$0.01），据 Zacks 报道。在去年同期，该公司每股收益为（$0.56）。</p>
</div><p>Get <strong>Rocket Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Rocket Pharmaceuticals Trading Down 1.1%</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 股价下跌 1.1%</h2>
</div><ul>
<li>3 Small-Cap Stocks That Are Ready to Rocket Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只准备大幅上涨的小型股</li>
</ul>
</div><p>RCKT stock traded down $0.04 during mid-day trading on Friday, reaching $3.63. 3,682,797 shares of the stock traded hands, compared to its average volume of 2,125,075. Rocket Pharmaceuticals has a 52-week low of $2.19 and a 52-week high of $7.39. The stock's fifty day moving average is $4.09 and its 200-day moving average is $3.69. The company has a market cap of $396.11 million, a P/E ratio of -1.94 and a beta of 0.52. The company has a current ratio of 6.38, a quick ratio of 6.38 and a debt-to-equity ratio of 0.07.</p>
<div class="lb-trans"><p>周五午盘交易中，RCKT 股票下跌 $0.04，报 $3.63。该股票成交量为 3,682,797 股，较其平均成交量 2,125,075 股有所增加。Rocket Pharmaceuticals 的 52 周低点为 $2.19，52 周高点为 $7.39。该股票的 50 日移动平均线为 $4.09，200 日移动平均线为 $3.69。公司的市值为 $3.9611 亿，市盈率为 -1.94，贝塔值为 0.52。公司的流动比率为 6.38，速动比率为 6.38，债务与股本比率为 0.07。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of analysts recently commented on RCKT shares. Cantor Fitzgerald boosted their target price on shares of Rocket Pharmaceuticals from $8.00 to $10.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, February 27th. The Goldman Sachs Group raised their target price on shares of Rocket Pharmaceuticals to $3.00 and gave the stock a &#34;sell&#34; rating in a report on Monday, March 2nd. Bank of America lifted their price target on shares of Rocket Pharmaceuticals from $8.00 to $9.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday, March 30th. Wall Street Zen cut Rocket Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Sunday, March 8th. Finally, Lifesci Capital upgraded Rocket Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Rocket Pharmaceuticals presently has a consensus rating of &#34;Hold&#34; and an average target price of $11.54.</p>
<div class="lb-trans"><p>多位分析师最近对 RCKT 股票发表了评论。Cantor Fitzgerald 将 Rocket Pharmaceuticals 的目标价从 $8.00 上调至 $10.00，并在 2 月 27 日的报告中给予该股票 “超配” 评级。高盛集团在 3 月 2 日的报告中将 Rocket Pharmaceuticals 的目标价上调至 $3.00，并给予该股票 “卖出” 评级。美国银行在 3 月 30 日的研究报告中将 Rocket Pharmaceuticals 的目标价从 $8.00 上调至 $9.00，并给予该股票 “买入” 评级。Wall Street Zen 在 3 月 8 日的报告中将 Rocket Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。最后，Lifesci Capital 在 2 月 26 日的研究报告中将 Rocket Pharmaceuticals 的评级上调至 “强烈买入”。一位投资分析师给予该股票 “强烈买入” 评级，八位分析师给予 “买入” 评级，六位分析师给予 “持有” 评级，三位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Rocket Pharmaceuticals 目前的共识评级为 “持有”，平均目标价为 $11.54。</p>
</div><p><strong>Read Our Latest Report on Rocket Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Rocket Pharmaceuticals 的最新报告</strong></p>
</div><h2>Insider Activity at Rocket Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 的内部活动</h2>
</div><p>In other news, General Counsel Martin Wilson sold 12,253 shares of the business's stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,557.43. Following the sale, the general counsel owned 683,376 shares in the company, valued at $2,261,974.56. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CEO Gaurav Shah sold 12,279 shares of the company's stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,643.49. Following the completion of the sale, the chief executive officer owned 1,052,045 shares of the company's stock, valued at approximately $3,482,268.95. This trade represents a 1.15% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 29,415 shares of company stock worth $97,398. 21.30% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席法律顾问 Martin Wilson 于 2 月 13 日出售了 12,253 股公司的股票，交易发生在该日。股票以平均价格 $3.31 出售，总交易额为 $40,557.43。出售后，首席法律顾问持有 683,376 股公司股票，价值约 $2,261,974.56。此次交易使其持股减少了 1.76%。该交易已在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，首席执行官 Gaurav Shah 于 2 月 13 日出售了 12,279 股公司的股票，交易发生在该日。股票以平均价格 $3.31 出售，总交易额为 $40,643.49。出售完成后，首席执行官持有 1,052,045 股公司的股票，价值约 $3,482,268.95。此次交易使其持股减少了 1.15%。该销售的 SEC 文件提供了更多信息。在过去三个月中，内部人士出售了 29,415 股公司股票，价值 $97,398。目前，21.30% 的股票由内部人士持有。</p>
</div><h2>Institutional Trading of Rocket Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 的机构交易</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the business. MPM Bioimpact LLC raised its position in Rocket Pharmaceuticals by 141.2% during the second quarter. MPM Bioimpact LLC now owns 3,903,081 shares of the biotechnology company's stock valued at $9,563,000 after buying an additional 2,284,816 shares during the period. Qube Research &amp; Technologies Ltd grew its stake in Rocket Pharmaceuticals by 690.8% during the 2nd quarter. Qube Research &amp; Technologies Ltd now owns 1,548,262 shares of the biotechnology company's stock valued at $3,793,000 after acquiring an additional 1,352,469 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Rocket Pharmaceuticals by 52.0% in the 3rd quarter. Millennium Management LLC now owns 3,570,391 shares of the biotechnology company's stock valued at $11,639,000 after purchasing an additional 1,221,554 shares during the period. Opaleye Management Inc. acquired a new position in shares of Rocket Pharmaceuticals in the 4th quarter valued at about $3,352,000. Finally, JPMorgan Chase &amp; Co. lifted its position in shares of Rocket Pharmaceuticals by 73.6% in the third quarter. JPMorgan Chase &amp; Co. now owns 2,097,033 shares of the biotechnology company's stock worth $6,836,000 after purchasing an additional 889,231 shares in the last quarter. Institutional investors and hedge funds own 98.39% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近调整了对该公司的持股。MPM Bioimpact LLC 在第二季度将其在 Rocket Pharmaceuticals 的持股增加了 141.2%。MPM Bioimpact LLC 目前拥有 3,903,081 股该生物技术公司的股票，价值 $9,563,000，此前在该期间内又购买了 2,284,816 股。Qube Research &amp; Technologies Ltd 在第二季度将其在 Rocket Pharmaceuticals 的持股增加了 690.8%。Qube Research &amp; Technologies Ltd 目前拥有 1,548,262 股该生物技术公司的股票，价值 $3,793,000，此前在上个季度又收购了 1,352,469 股。Millennium Management LLC 在第三季度将其在 Rocket Pharmaceuticals 的持股增加了 52.0%。Millennium Management LLC 目前拥有 3,570,391 股该生物技术公司的股票，价值 $11,639,000，此前在该期间内又购买了 1,221,554 股。Opaleye Management Inc. 在第四季度收购了 Rocket Pharmaceuticals 的新头寸，价值约 $3,352,000。最后，摩根大通在第三季度将其在 Rocket Pharmaceuticals 的持股增加了 73.6%。摩根大通目前拥有 2,097,033 股该生物技术公司的股票，价值 $6,836,000，此前在上个季度又购买了 889,231 股。机构投资者和对冲基金持有该公司 98.39% 的股票。</p>
</div><h2>Rocket Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于开发针对罕见遗传性儿童疾病的基因疗法。该公司采用专有的腺相关病毒（AAV）和慢病毒载体平台，为患有遗传缺陷的患者提供功能性基因拷贝。其项目针对一系列疾病，包括范可尼贫血、白细胞粘附缺陷 I 型和丹农病，旨在提供一次性治疗，解决疾病的根本原因，而不仅仅是管理症状。</p>
</div><p>The company's pipeline comprises multiple product candidates in various stages of development.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个处于不同开发阶段的候选产品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Rocket Pharmaceuticals</li>
<li>Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due</li>
<li>Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches</li>
<li>Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money</li>
<li>Water Infrastructure: Why This Boring Sector Could Get Exciting</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Rocket Pharmaceuticals</li>
<li>巴菲特花了 60 年忽视科技，账单即将到来</li>
<li>对黄金感到兴奋但不确定其走势？试试这三种方法</li>
<li>美元处于三年低点：三家出口商悄然印钞</li>
<li>水务基础设施：为什么这个乏味的行业可能会变得令人兴奋</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=RCKT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Rocket Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Rocket Pharmaceuticals 吗？</h2>
</div><p>Before you consider Rocket Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Rocket Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rocket Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Rocket Pharmaceuticals 并不在名单上。</p>
</div><p>While Rocket Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rocket Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Rocket Pharmaceuticals（纳斯达克股票代码：RCKT）公布财报结果